Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

By sjmartinez • May 5, 2023

Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbé C, Joshi H, Snyder W, Mehnert JM. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J Immunother Cancer. 2023 May;11(5):e006270. doi: 10.1136/jitc-2022-006270. PMID: 37142291.

Tags: Hematology/Oncology, immunotherapy, melanoma, oncolytic virotherapy, oncolytic viruses, Publications

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

Stefanoudakis D, Frountzas M, Schizas D, Michalopoulos NV, Drakaki A, Toutouzas KG. Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. Curr Issues Mol[...]

[68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions

Ludwig V, Maliha PG, Shen J, Tonnelet D, Raman S, Litwin MS, Calais J. [68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic[...]

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights

Rose MG, Kennedy EB, Abou-Alfa GK, Finn RS, Gade T, Kelley RK, Taddei T, Gordan JD. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update[...]